Unknown

Dataset Information

Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.


ABSTRACT:

Background and purpose

Esophageal cancer has a persistently low 5-year survival rate and has recently been classified as a cancer of unmet need by Cancer Research UK. Consequently, new approaches to therapy are urgently required. Here, we tested the hypothesis that an ATR inhibitor, VX-970, used in combination with standard therapies for esophageal cancer could improve treatment outcome.

Material and methods

Using esophageal cancer cell lines we evaluated the efficacy of combining VX-970 with cisplatin and carboplatin in vitro and with radiation in vitro and in vivo. Radiation experiments were also carried out in hypoxic conditions to mimic the tumor microenvironment.

Results

Combining VX-970 with cisplatin, carboplatin and radiation increased tumor cell kill in vitro

SUBMITTER: Leszczynska KB 

PROVIDER: S-EPMC5154234 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature